Literature DB >> 19379126

Antisense oligonucleotide pharmacokinetics and metabolism.

Richard S Geary1.   

Abstract

BACKGROUND: The use of oligonucleotides as therapeutic agents has elicited a great deal of interest. Basic understanding and evaluation of the pharmacokinetic properties of oligonucleotides is foundational to their appropriate design and application.
OBJECTIVE: To review the primary pharmacokinetic properties that drive successful use and delivery of oligonucleotides.
METHODS: The primary data set available in the published literature for summarizing the pharmacokinetic properties of oligonucleotides exists for single strand phosphorothioate antisense oligonucleotides and their chimeric chemical modifications (second generation). Where possible, data from other classes of compounds are contrasted with this base class. RESULTS/
CONCLUSION: Although there are several different classes of oligonucleotides being developed as therapeutic agents, their pharmacokinetic properties by class are primarily a function of their backbone chemistry and the resulting chemical relationship to biological stability and plasma protein binding properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19379126     DOI: 10.1517/17425250902877680

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  98 in total

1.  Kinetics of DNA and RNA Hybridization in Serum and Serum-SDS.

Authors:  Elton Graugnard; Amber Cox; Jeunghoon Lee; Cheryl Jorcyk; Bernard Yurke; William L Hughes
Journal:  IEEE Trans Nanotechnol       Date:  2010-09-01       Impact factor: 2.570

Review 2.  MicroRNAs regulating lipid metabolism in atherogenesis.

Authors:  K J Rayner; C Fernandez-Hernando; K J Moore
Journal:  Thromb Haemost       Date:  2012-01-25       Impact factor: 5.249

3.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

Review 4.  Remedial applications of silencing ribonucleic acids and modalities for its delivery to the kidneys--a review.

Authors:  Dongjie Wang; Yanfen Lv; Huifang Zhu; Guifeng Lv; Jiyi Huang
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

5.  PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures.

Authors:  Xueguang Lu; Ke Zhang
Journal:  Nano Res       Date:  2018-07-06       Impact factor: 8.897

Review 6.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

Review 7.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

8.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

Review 9.  MicroRNAs in the midst of myeloid signal transduction.

Authors:  Sara L Stoffers; Sara E Meyer; H Leighton Grimes
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

Review 10.  Therapeutic targeting of microRNAs: current status and future challenges.

Authors:  Zhonghan Li; Tariq M Rana
Journal:  Nat Rev Drug Discov       Date:  2014-07-11       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.